Eliglustat tartrate

Status: Currently recruiting participants

Note: The Phase III study has been expanded to accommodate those who have been affected by the Cerezyme shortage.

A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Been Stabilized With Cerezyme. Genz-112638 is a small molecule drug developed as an oral therapy which acts to specifically inhibit production of this storage material in Gaucher cells. (Information obtained from www.cerezyme.com).

Read latest press release

Genz-112638 Trial locations - United States
(Information from www.clinicaltrials.gov 10/13/09)

California
Tower Hematology Oncology Medical Group - Recruiting
Beverly Hills, California

UCSF MS Center - Not yet recruiting
San Francisco, California

Florida
Northwest Oncology Hematology Associates PA - Recruiting
Coral Springs, Florida

Georgia
Emory University Medical Genetics - Not yet recruiting
Decatur, Georgia

New York
Mount Sinai School of Medicine - Recruiting
New York, New York

North Carolina
Duke University Medical Center - Recruiting
Durham, North Carolina